CN110361486A - Aripiprazole drug substance concentration monitor kit and its detection method in a kind of blood - Google Patents
Aripiprazole drug substance concentration monitor kit and its detection method in a kind of blood Download PDFInfo
- Publication number
- CN110361486A CN110361486A CN201910671626.8A CN201910671626A CN110361486A CN 110361486 A CN110361486 A CN 110361486A CN 201910671626 A CN201910671626 A CN 201910671626A CN 110361486 A CN110361486 A CN 110361486A
- Authority
- CN
- China
- Prior art keywords
- content
- concentration
- sample
- methanol
- aripiprazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/16—Injection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8624—Detection of slopes or peaks; baseline correction
- G01N30/8631—Peaks
Abstract
The present invention relates to medical detection fields, more particularly to aripiprazole in treatment drug surveillance kit in a kind of blood based on multidimensional on-line solid phase extraction liquid-phase chromatographic analysis technological development, the method that accurate quantitative analysis detection is more specifically carried out to aripiprazole drug substance concentration in blood using on-line solid phase extraction and multidimensional liquid-phase chromatographic analysis technology.Kit includes calibration object reagent, quality-control product reagent, treatment fluid, extract liquor, cleaning solution, eluent.Therapeutic Drug Monitoring kit of the invention, blood sample only need centrifugal treating, and repetition detection variability is small, and Stability and veracity is high, and testing cost is low, and every methodology index can meet the needs of aripiprazole in treatment drug surveillance in blood, easy to spread.
Description
Technical field
The present invention relates to medical detection fields, more particularly to one kind to be based on multidimensional on-line solid phase extraction liquid-phase chromatographic analysis
Aripiprazole in treatment drug surveillance kit in the blood of technological development more specifically uses on-line solid phase extraction and multidimensional
The method that liquid-phase chromatographic analysis technology carries out accurate quantitative analysis monitoring to aripiprazole drug substance concentration in blood.
Background technique
Aripiprazole is a kind of novel atypia antipsychotic drug, has bidirectional modulation to DA nervous system
Effect, is the stabilizer of DA mediator.There is very high affinity with D2, D3,5-HT1A and 5-HT2A receptor.By to D2 and 5-
The partial agonist of HT1A receptor acts on and generates to the antagonism of 5-HT2A receptor antipsychotic effect.A Li piperazine
The effective blood drug concentration of azoles is 0.15-0.5mg/L, as blood concentration > 0.5mg/L, toxic side effect enhancing.It is common bad anti-
It should be that adverse reaction mainly has headache, anxiety insomnia is drowsiness, and aconuresis is cathisophobiaed.Due to aripiprazole in treatment window compared with
Narrow, there are biggish individual differences for internal metabolic process, so being adjustment dosage to the detection of its blood drug concentration, reduce
The important references of adverse reaction, are of great significance in clinical application.The common side of aripiprazole in treatment drug test at present
Method has: ultraviolet spectrophotometry, high performance liquid chromatography, Liquid Chromatography-Mass Spectrometry etc..In numerous methods, liquid phase
Chromatography is to measure the most accurate method of Aripiprazole.Previous methods are there are complex pretreatment, qualitative, quantitative is not accurate enough, at
The problems such as this height, long or high to experimenter's technical requirements analysis time.
Summary of the invention
An object of the present invention is in view of the deficiencies of the prior art, to provide a kind of based on multidimensional on-line solid phase extraction liquid phase
Aripiprazole in treatment drug surveillance kit in the blood of chromatographic technique exploitation, to meet aripiprazole in treatment medicine in blood
The needs of object monitoring.
It is a further object of the present invention to provide the methods using kit monitoring Aripiprazole blood drug concentration.
The present invention is that technical solution used by solving its technical problem is:
Aripiprazole drug substance concentration monitor kit in a kind of blood, it is characterised in that: the kit includes calibration object
Reagent, quality-control product reagent, treatment fluid, extract liquor, cleaning solution, eluent.Further, the calibration object reagent is piperazine containing A Li
The animal blood serum of azoles freeze-dried powder, stabilizer and plastotype agent, concentration range of the Aripiprazole freeze-dried powder in animal blood serum are
0.06~2mg/L, the concentration of the stabilizer are 10~30g/L, and the concentration of the plastotype agent is 10~30g/L；
Further, the quality-control product reagent is the animal blood serum of freeze-dried powder containing Aripiprazole, stabilizer and plastotype agent, institute
Stating concentration range of the Aripiprazole freeze-dried powder in animal blood serum is 0.06~2mg/L, the concentration of the stabilizer is 10~
30g/L, the concentration of the plastotype agent are 10~30g/L；
Preferably, the concentration of the stabilizer is 15~25g/L, and the concentration of the plastotype agent is 15~25g/L；
Further, the sample treatment solution is one or more of acetate buffer solution, acetonitrile and methanol
Mixture aqueous solution, the content of ammonium acetate is 0.1 ‰~0.3 ‰ in the acetate buffer solution.The methanol contains
Amount is 5%~15%, and the content of the acetonitrile is 5%~15%.
Further, the extract liquor includes extract liquor H1 and extract liquor H2；
Further, the extract liquor H1 is one or more of acetate buffer solution, acetonitrile and methanol
The aqueous solution of mixture, the acetate buffer solution content are 0.1 ‰~0.3 ‰, the content of the methanol is 3%~
10%, the content of the acetonitrile is 2%~8%.
Further, the extract liquor H2 is one or more of acetate buffer solution, acetonitrile and methanol
The aqueous solution of mixture, the content of ammonium acetate is 0.05 ‰~0.15 ‰ in the acetate buffer solution.The methanol contains
Amount is 30%~50%, and the content of the acetonitrile is 40%~70%.
Further, the cleaning solution is the aqueous solution of methanol or acetonitrile or two kinds of mixtures, the content of the methanol
It is 0%~40%, the content of the isopropanol is 0%~20%, and the content of the acetonitrile is 0%~50%.
Further, the eluent includes eluent A, eluent B and eluent C；
Further, the eluent A is the mixed of one or more of acetate buffer solution, acetonitrile and methanol
The aqueous solution of object is closed, the content of ammonium acetate is 0.05 ‰~0.15 ‰ in the acetate buffer solution, the content of the methanol
It is 0%~15%, the content of the acetonitrile is 70%~90%；
Further, the mixing of one or more of the eluent B acetate buffer solution, acetonitrile and methanol
The aqueous solution of object, the content of ammonium acetate is 0.1 ‰~0.3 ‰ in the acetate buffer solution, and the content of the methanol is 0%
~10%, the content of the acetonitrile is 5%~15%；The pH of the eluent B is 3~5；
Further, the mixing of one or more of the eluent C acetate buffer solution, acetonitrile and methanol
The aqueous solution of object, the content of ammonium acetate is 0.1 ‰~0.3 ‰ in the acetate buffer solution, and the content of the methanol is 0%
~10%, the content of the acetonitrile is 5%~15%；The pH of the eluent B is 6~8.
The acetate buffer solution includes the mixture of one or two of acetic acid, ammonium acetate, ammonium hydroxide or more.
Further, the stabilizer is bovine serum albumin(BSA) (BSA)；The plastotype agent mannitol and sucrose are a kind of
Or two kinds of mixture, the ratio of the mixture of the mannitol and sucrose is 1:2~5.
Further, the detection method of the kit includes the following steps: that blood sample takes supernatant after being centrifuged
Sample introduction, compensation is combined before and after carrying out in-line purification, enrichment, desorption and column by on-line solid phase extraction column, then passes through Vavle switching side
Target analytes in blood sample are sent into analytical column and are separated by formula, finally by UV detector or diode array
The analysis detections such as detector or mass detector, are calculated using calibration curve method, and drug is dense in final acquisition blood sample
Angle value.
Calculation formula is as follows: linear regression equation: y=ax+b, and wherein a is slope, and b is intercept, and y is actual measurement peak face
Product, x are mark concentration, and sample results calculate: the Aripiprazole peak area of sample being substituted into calibration curve equation, is calculated in sample
Aripiprazole concentration；
Specific step is as follows:
(1) 1~4mL of sample to be tested is taken, 10min is centrifuged in the case where centrifugal speed is 3000~5000rpm, supernatant is taken to obtain
Serum or blood plasma；
(2) above-mentioned serum or blood plasma are taken, 1.0ml is pipetted and is added in sample bottle, be put into autosampler sample introduction 100ul into
Row liquid chromatogram quantitative detection；
Chromatographic condition: extraction column: SLCZ column (30 × 4.6mm, 10 μm of partial sizes)；Analytical column: C18 column (150 × 4.6mm, 5 μ
M partial size)；Mobile phase: extract liquor H1, extract liquor H2, eluent A, eluent B and eluent C；Column temperature: 35 DEG C；Sample volume: 100
μL；Wavelength: 220nm.
(3) drug concentration in sample is calculated according to above-mentioned formula.
The present invention has the advantages that
1, it is carried out using drug concentration of the multidimensional on-line solid phase extraction liquid-phase chromatographic analysis technology to Aripiprazole in blood
Accurate quantitative analysis detection, testing result are Aripiprazole proto-drug concentration, can more accurately illustrate that drug concentration-effect treatment-is bad
React the relationship before three；
2, blood sample is reduced brought by pre-treatment merely through centrifugal treating using blood plasma or serum direct injected
Error and personnel's operating error improve the accuracy, repeatability and the rate of recovery of quantitative result, greatly shorten detection time, make
Detection process is easy quickly, and experimental cost reduces, and more conducively detects in clinical treatment to the drug concentration of patient's body.
3, kit provided by the invention assesses Aripiprazole by the drug concentration of Aripiprazole in detection blood
Clinical drug effect.Application i.e. the present invention also provides the kit in assessment anti-fungal infection clinical drug curative effect.
Detailed description of the invention
Fig. 1 is Aripiprazole chromatogram in Quality Control sample in embodiment；
Fig. 2 is Aripiprazole representative standard curve figure in embodiment；
Fig. 3 is Aripiprazole chromatogram in serum sample in embodiment.
Specific embodiment
In order to be easy to understand the technical means, the creative features, the aims and the efficiencies achieved by the present invention, tie below
Diagram and specific embodiment are closed, the present invention is further explained.
One, the preparation of aripiprazole in treatment drug surveillance kit:
Standard curve reagent: wherein Aripiprazole is to be configured to a system containing 2% stabilizer and the animal blood serum of 2% moulding agent
Column concentration, respectively 0.06mg/L, 0.15mg/L, 0.40mg/L, 0.80mg/L, 1.5mg/L, 2.0mg/L, every bottle of packing
1.0ml.The above component is lyophilized to be saved in measurement bottom of bottle.
Quality-control product reagent: wherein Aripiprazole is configured to high, normal, basic with the animal blood serum containing 2% stabilizer and 2% moulding agent
Three concentration, respectively 0.10mg/L, 0.6mg/L, 1.5mg/L, every bottle of packing 1.0ml.The above component is lyophilized in measurement bottle
Bottom saves.
Sample treatment solution: precision weighs 0.18g ammonium acetate, sets in 1000mL volumetric flask, adds distilled water 700ml to dissolve, adds
Acetic acid adjusts pH value 5.0, then plus acetonitrile 100ml and methanol 100ml, then plus distilled water is diluted to scale to get dispensing, patch
Label label, completes operation.
Extract liquor H1: precision weighs 0.18g ammonium acetate, sets in 1000mL volumetric flask, and distilled water 700ml is added to dissolve, then plus
Acetonitrile 200mL, then plus distilled water is diluted to scale to get packing, labeling label completes operation.
Extract liquor H2: precision weighs 0.18g ammonium acetate, sets in 1000mL volumetric flask, and distilled water 100ml is added to dissolve, then plus
Acetonitrile 800ml, then plus distilled water is diluted to scale to get packing, labeling label completes operation.
Cleaning solution: precision weighs methanol 200ml and acetonitrile 400ml, sets in 1000mL volumetric flask, and distilled water is added to be diluted to quarter
Degree is to get packing, labeling label completes operation.
Eluent A: precision weighs 0.18g ammonium acetate, sets in 1000mL volumetric flask, adds distilled water 250ml to dissolve, then plus second
Nitrile 700mL, then plus distilled water is diluted to scale to get packing, labeling label completes operation.
Eluent B: precision weighs 0.18g ammonium acetate, sets in 1000mL volumetric flask, adds distilled water 700ml to dissolve, adds acetic acid
PH value is adjusted to 3.0, then plus acetonitrile 50ml, then plus distilled water is diluted to scale to get packing, labeling label completes behaviour
Make.
Eluent C: precision weighs 0.18g ammonium acetate, sets in 1000mL volumetric flask, adds distilled water 700ml to dissolve, adds 10%
Ammonium hydroxide adjusts pH value to 7.5, then plus acetonitrile 50ml, then plus distilled water is diluted to scale to get packing, labeling label is completed
Operation.
Two, the detecting step using above-mentioned monitoring reagent box is as follows:
1, it is applicable in instrument
Fully automatic therapy drug test analysis system (SLC), high performance liquid chromatograph (HPLC), liquid chromatography-tandem matter
Spectrometer (LC-MS/MS).
2, sample requirement
Venous whole sample is acquired, is placed in anticoagulant tube, 2~8 DEG C of refrigerators is placed in immediately and seals standby survey up for safekeeping.
3, the method for inspection
Sample pretreatment:
Sample treatment solution is taken, 0.5ml is quantitatively pipetted and is added in sample reagent bottle；Sample to be tested at least 4mL is taken, is being centrifuged
Speed is to be centrifuged 10min under 4000rpm, pipettes supernatant 1.0ml and is added in sample bottle, and vortex mixes, and is put into autosampler
Middle sample introduction, and carry out liquid chromatogram quantitative detection；
Chromatographic condition:
On-line extraction column: SLCZ column (30 × 4.6mm, 10 μm of partial sizes)；
On-line analysis column: C18 column (150 × 4.6mm, 5 μm of partial sizes)；
Mobile phase: extract liquor H1, extract liquor H2, eluent A, eluent B and eluent C；
Column temperature: 35 DEG C；Sample volume: 100 μ L；Wavelength: 220nm.
1 condition of gradient elution of table
Measuring method:
After taking calibration object, quality-control product, sample to be tested to carry out Sample pretreatment, 100 μ L of supernatant sample introduction is taken to carry out chromatography fixed
Amount analysis, records chromatographic peak area.
Quality Control requirement:
Every 1 analysis 1 standard curve of this retinue of lot sample (6 each 1 of various concentration value calibration product samples) and 6 Quality Control samples
This (each 2 of high, medium and low concentration).Quality-control product sample measures result error should be less than 10%, at most allow 1/3 quality-control product sample
This result is more than above-mentioned limit, but there can be no in same concentration quality-control product sample.As quality-control product sample measures result is not inconsistent
Above-mentioned requirements are closed, then the analysis batch sample tests cancel, and detect again.
4, result calculates
As shown in Figs. 1-3；
Specification Curve of Increasing:
With the calibration object concentration (0.06,0.15,0.40,0.80,1.5,2.0mg/L) of 6 different mark concentration for horizontal seat
It marks (x), using the actual measurement peak area of 6 calibration object samples as ordinate (y), draws standard curve.
The fitting of calibration curve equation:
With the actual measurement peak area (y) of 6 calibration object samples to mark concentration (x) using weighting (1/x2) least square method into
Row linear regression.Linear regression equation: Y=0.0008X-0.0133, wherein 0.0008 is slope, -0.0133 is intercept,
And related coefficient (r) is calculated, r should be not less than 0.9900.R is 0.9957.The calculating of the rate of recovery:
The Aripiprazole peak area of quality-control product sample measures is substituted into above-mentioned standard curvilinear equation, calculates quality-control product sample
Aripiprazole measures concentration.The calculation formula of the quality-control product sample rate of recovery are as follows: the rate of recovery (%)=measurement concentration/mark concentration ×
100, the rate of recovery (%) should be in 100 ± 15% ranges.The rate of recovery: 96.5%
Sample results calculate:
The Aripiprazole peak area of sample is substituted into calibration curve equation, calculates the aripiprazole drug substance concentration of sample.Meter
Calculation show that aripiprazole drug substance concentration is 197.12ng/mL.
It summarizes, under the process conditions, the calibration curve coefficient correlation and the quality-control product rate of recovery of Aripiprazole meet rule
It is fixed, it is ensured that the accuracy of this method institute sample result.
The basic principles, main features and advantages of the present invention have been shown and described above.The technology of the industry
Personnel are it should be appreciated that the present invention is not limited to the above embodiments, and the above embodiments and description only describe this
The principle of invention, various changes and improvements may be made to the invention without departing from the spirit and scope of the present invention, these changes
Change and improvement all fall within the protetion scope of the claimed invention.The claimed scope of the invention by appended claims and its
Equivalent defines.
Claims (10)
1. aripiprazole drug substance concentration monitor kit in a kind of blood, it is characterised in that: the kit includes calibration object examination
Agent, quality-control product reagent, treatment fluid, extract liquor, cleaning solution, eluent.
2. kit according to claim 1, it is characterised in that: the calibration object reagent be freeze-dried powder containing Aripiprazole,
The animal blood serum of stabilizer and plastotype agent, concentration range of the Aripiprazole freeze-dried powder in animal blood serum are 0.06~2mg/
L, concentration gradient are 0.06~2mg/L；The concentration of the stabilizer is 10~30g/L, the concentration of the plastotype agent is 10~
30g/L；
The quality-control product reagent is the animal blood serum of freeze-dried powder containing Aripiprazole, stabilizer and plastotype agent, and the Aripiprazole freezes
Concentration range of the dry powder in animal blood serum is 0.06~2mg/L, and the concentration of the stabilizer is 10~30g/L, the plastotype
The concentration of agent is 10~30g/L；
The concentration of the stabilizer is 15~25g/L, and the concentration of the plastotype agent is 15~25g/L.
3. kit according to claim 1, it is characterised in that: the concentration of the stabilizer is 10~30g/L, the modeling
The concentration of type agent is 10~30g/L.
4. kit according to claim 1, it is characterised in that: the sample treatment solution is acetate buffer solution, second
The aqueous solution of the mixture of one or more of nitrile and methanol, the content of ammonium acetate is in the acetate buffer solution
0.1 ‰~0.3 ‰, the content of the methanol is 5%~15%, and the content of the acetonitrile is 5%~15%.
5. kit according to claim 1, it is characterised in that: the extract liquor includes extract liquor H1 and extract liquor H2；
The extract liquor H1 is the water-soluble of the mixture of one or more of acetate buffer solution, acetonitrile and methanol
Liquid, the content of ammonium acetate is 0.1 ‰~0.3 ‰ in the acetate buffer solution, and the content of the methanol is 3%~10%,
The content of the acetonitrile is 2%~8%.
The extract liquor H2 is the water-soluble of the mixture of one or more of acetate buffer solution, acetonitrile and methanol
Liquid, the content of ammonium acetate is 0.05 ‰~0.15 ‰ in the acetate buffer solution, the content of the methanol is 30%~
50%, the content of the acetonitrile is 40%~70%.
6. kit according to claim 1, it is characterised in that: the cleaning solution is methanol or acetonitrile or two kinds of mixing
The aqueous solution of object.
7. kit according to claim 1, it is characterised in that: the eluent include eluent A, eluent B and
Eluent C；
The eluent A is the aqueous solution of the mixture of one or more of acetate buffer solution, acetonitrile and methanol,
The content of ammonium acetate is 0.05 ‰~0.15 ‰ in the acetate buffer solution, and the content of the methanol is 0%~15%, institute
The content for stating acetonitrile is 70%~90%；
The aqueous solution of the mixture of one or more of the eluent B acetate buffer solution, acetonitrile and methanol, institute
The content for stating ammonium acetate in acetate buffer solution is 0.1 ‰~0.3 ‰, and the content of the methanol is 0%~10%, the second
The content of nitrile is 5%~15%；The pH of the eluent B is 3~5；
The aqueous solution of the mixture of one or more of the eluent C acetate buffer solution, acetonitrile and methanol, institute
The content for stating ammonium acetate in acetate buffer solution is 0.1 ‰~0.3 ‰, and the content of the methanol is 0%~10%, the second
The content of nitrile is 5%~15%；The pH of the eluent B is 6~8.
8. according to kit described in claim 4~7 any one, it is characterised in that: the acetate buffer solution includes vinegar
The mixture of the one or two of acid, Ammoniom-Acetate or more.
9. kit according to claim 2 or 3, it is characterised in that: the stabilizer is bovine serum albumin(BSA)
(BSA)；The ratio of the mixture of the mixture of the plastotype agent mannitol and sucrose one or two, the mannitol and sucrose
Example is 1:2~5.
10. a kind of detection method of kit described in claim 1, include the following steps: that blood sample takes after being centrifuged on
Clear liquid sample introduction, compensation is combined before and after carrying out in-line purification, enrichment, desorption and column by on-line solid phase extraction column, then is cut by valve
Changing mode will separate in target analytes feeding analytical column in blood sample, finally by UV detector or diode
The analysis detections such as array detector or mass detector, are calculated using calibration curve method, final to obtain blood sample Chinese medicine
Object concentration value；
Calculation formula is as follows: linear regression equation: y=ax+b, and wherein a is slope, and b is intercept, and y is actual measurement peak area, x
To indicate concentration, sample results are calculated: the Aripiprazole peak area of sample is substituted into calibration curve equation, calculate in sample Ah
Vertical piperazine azoles concentration；
Specific step is as follows:
(1) 1~4mL of sample to be tested is taken, 10min is centrifuged in the case where centrifugal speed is 3000~5000rpm, supernatant is taken to obtain serum
Or blood plasma；
(2) above-mentioned serum or blood plasma are taken, 1.0ml is pipetted and is added in sample bottle, sample introduction 100ul in autosampler is put into and carries out liquid
The detection of phase chromatogram quantification；
(3) drug concentration in sample is calculated according to above-mentioned formula.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910671626.8A CN110361486A (en) | 2019-07-24 | 2019-07-24 | Aripiprazole drug substance concentration monitor kit and its detection method in a kind of blood |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910671626.8A CN110361486A (en) | 2019-07-24 | 2019-07-24 | Aripiprazole drug substance concentration monitor kit and its detection method in a kind of blood |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110361486A true CN110361486A (en) | 2019-10-22 |
Family
ID=68220696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910671626.8A Withdrawn CN110361486A (en) | 2019-07-24 | 2019-07-24 | Aripiprazole drug substance concentration monitor kit and its detection method in a kind of blood |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110361486A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111610158A (en) * | 2020-05-08 | 2020-09-01 | 浙江大学 | Method for detecting chromogenic impurities in production process of paracetamol |
-
2019
- 2019-07-24 CN CN201910671626.8A patent/CN110361486A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111610158A (en) * | 2020-05-08 | 2020-09-01 | 浙江大学 | Method for detecting chromogenic impurities in production process of paracetamol |
| CN111610158B (en) * | 2020-05-08 | 2021-10-15 | 浙江大学 | Method for detecting chromogenic impurities in production process of paracetamol |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Omar et al. | Validated spectrofluorimetric method for determination of selected aminoglycosides | |
| CN105717237B (en) | The detection method of GABA, Glu, DA, 5-HT and Capillary zone electropheresis in a kind of serum | |
| CN109030658B (en) | Method for detecting fructo-oligosaccharide and raffinose in infant milk powder | |
| WO2023124924A1 (en) | Method for detecting residual solvent in pingyangmycin hydrochloride bulk drug | |
| CN107607632A (en) | The method of residual solvent in extraction of ginkgo biloba leaves by headspace gas | |
| CN105277643A (en) | Detection method for compound radix salviae miltiorrhizae dripping pills through quantitative analysis of multiple components by single marker | |
| CN110361482A (en) | Linezolid monitor drug concentration kit and its detection method in a kind of blood | |
| CN110361485A (en) | Oxcarbazepine monitor drug concentration kit and its detection method in a kind of blood | |
| CN110361481A (en) | Vancomycin monitor drug concentration kit and its detection method in a kind of blood | |
| CN110361488A (en) | Lamotrigine monitor drug concentration kit and its detection method in a kind of blood | |
| CN106033079B (en) | Method for detecting related substance imidazole in starting material F of dabigatran etexilate mesylate | |
| CN110361484A (en) | Amiodarone monitor drug concentration kit and its detection method in a kind of blood | |
| CN113484430A (en) | Method for determining L-alanine isopropyl ester hydrochloride related substances by adopting high performance liquid chromatography | |
| CN110361486A (en) | Aripiprazole drug substance concentration monitor kit and its detection method in a kind of blood | |
| CN112710758A (en) | Method for detecting residual solvent in tapentadol hydrochloride raw material medicine | |
| CN101658550A (en) | Method for measuring content of selfheal oral liquid | |
| CN111122727A (en) | Method for simultaneously determining concentration of imatinib and imatinib metabolite in human plasma | |
| CN112782322A (en) | Method for simultaneously determining 8 anti-tuberculosis drugs in human plasma based on LC-MS (liquid chromatography-Mass Spectrometry) | |
| CN109307716A (en) | It is a kind of according to a detection method of the piperazine azoles in relation to substance | |
| CN110361489A (en) | Amitriptyline monitor drug concentration kit and its detection method in a kind of blood | |
| CN103543222A (en) | Reduning injection saccharide content detection method | |
| CN101034086B (en) | Method for detecting impurity in disodium creatine phosphate | |
| CN115356420A (en) | Pudilan anti-inflammatory tablet quality evaluation method based on one-test-multiple evaluation | |
| CN114264765B (en) | Analytical method for determining related substances in glimepiride intermediate by utilizing HPLC | |
| CN114280191A (en) | Method for detecting related substances in bis-cysteine and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20191022 |
|
| WW01 | Invention patent application withdrawn after publication |